A Phase IIa Open-label, Dose Confirmation Study of Single Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes(MDS).

Trial Profile

A Phase IIa Open-label, Dose Confirmation Study of Single Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes(MDS).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Clofarabine (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2011 Actual patient number (36) added as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 07 Jul 2010 Planned end date changed from 1 Jun 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top